Platelet uptake of the pheochromocytoma-scanning agent 131I-meta-iodobenzylguanadine.

Published

Journal Article

The pheochromocytoma-scanning agent 131I-meta-iodobenzylguanadine (131I-MIBG) was concentrated in the platelets of ten subjects undergoing scans for suspected pheochromocytomas. In vitro studies also demonstrated that 131I-MIBG was concentrated in platelets. In contrast to serotonin, which had maximum in vitro platelet uptake of one hour, the peak in vitro platelet uptake of 131I-MIBG did not occur until six hours. In vitro platelet 131I-MIBG uptake was decreased by 79% to 98% following the neuronal-uptake-blocking agent imipramine. These studies suggest that pheochromocytomas take up 131I-MIBG by a neuronal-pump mechanism. Further studies to determine if 131I-MIBG is taken up by other tumors with a neuronal-pump mechanism, such as carcinoid tumors, will be valuable.

Full Text

Duke Authors

Cited Authors

  • Feldman, JM; Frankel, N; Coleman, RE

Published Date

  • May 1, 1984

Published In

Volume / Issue

  • 33 / 5

Start / End Page

  • 397 - 399

PubMed ID

  • 6717272

Pubmed Central ID

  • 6717272

International Standard Serial Number (ISSN)

  • 0026-0495

Digital Object Identifier (DOI)

  • 10.1016/0026-0495(84)90135-5

Language

  • eng

Conference Location

  • United States